A pilot study has also shown that quizartnib is an effective treatment of newly diagnosed AML when combined with chemotherapy (a complete remission seen in 79% of patients) [171], and a phase III clinical trial is currently investigating the use of quizartnib in combination with chemotherapy in newly diagnosed FLT3-ITD AML (NCT02668653). This evidence concerns the gene FLT3 and acute myeloid leukemia.